ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ORGO
PMVP (42) NRXP (25) VTVT (24) NTHI (31) ⌘ Pro Terminal →

Organogenesis Holdings Inc. (Class A) (ORGO) — RQD Stock Rating Cockpit

$0.76 -1.64% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.76

Organogenesis Holdings Inc. (Class A) (ORGO) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $98.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ORGO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ORGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Organogenesis Holdings Inc. (Class A) (NASDAQ: ORGO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.76 (-1.64% 1D, market cap $98.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 8/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ORGO compare to PMVP and NRXP in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORGO carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 17.1%. By comparison, PMVP (PMV Pharmaceuticals Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $98.9M) and NRXP (NRX Pharmaceuticals Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $98.3M). Among the 5-stock peer group, ORGO leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ORGO?
▼

Per ORGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661181), Organogenesis Holdings Inc. (Class A) generated $564.2M in revenue (+17.0% YoY), $37.0M in net income, and -$24.5M in free cash flow against $598.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.76 (-0.49%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (3)SEC (9)Macro (6)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE-10.5% Base Target
$7 Bull$1 Base$1 Bear
📬 FREE ORGO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ORGO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY ORGO SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+9/20 pts (26% of score)

Altman Z-Score 2.09 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$1.21-15.7% Next Q
Q2 (-2Q)
39
Grade E$1.02-11.8% Next Q
Q3 (-1Q)
37
Grade E$0.90-15.6% Next Q
Current
34
Grade E$0.76-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ORGO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ORGO currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.31) and Max Pain ($0.80) forces dealer call-delta covering toward $7.43.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+1.08% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ORGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ORGO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
20.230 Oversold · 70 Hot
ALTMAN-Z SHIELDWATCH ZONE (1.8–3.0)
2.09>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$0.76H: $7
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on ORGO

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

17.1% ROIC with 42.0% gross margin and -23.21% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (45)

Altman-Z 2.09 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (28)

11/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like ORGO
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ORGO)

  • ✓Walkthrough of ORGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ORGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.31%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.82H $0.82L $0.76C $0.76VOL 760.3K
RES: $2.53SUP: $0.69SMA50: $1.31SMA200: $2.34
$4.35$3.37$2.39$1.41$0.43RES $2.53SUP $0.69$0.762026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ORGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ORGO Butterfly Map → + Track ORGO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +17.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ORGO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ORGO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ORGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ORGO)

Health Care Rank #636 of 1015 ⚔️ PMVP vs ORGO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ORGO vs. PMVP, NRXP, VTVT, NTHI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Organogenesis Holdings Inc. (Class A) (ORGO) ranks #636 by composite RQD confidence (34/100, grade E) and #654 by equity capitalization ($98.8M). Within this direct 5-issuer industry benchmark cohort, ORGO leads on earnings valuation at N/A trailing P/E, while ORGO leads on capital efficiency and profitability with 17.1% ROIC and — gross margin. PMVP currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with ORGO at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ORGO ACTIVE
Organogenesis Holdings Inc. (Class A)
E 34/100 — — 17.1% -1.64% $98.8M Benchmark Subject
PMVP
PMV Pharmaceuticals Inc.
D- 42/100 — — -35.0% +4.58% $98.9M /pmvp-vs-orgo →
NRXP
NRX Pharmaceuticals Inc.
E 25/100 — 58.8% -35.0% -4.40% $98.3M /nrxp-vs-orgo →
VTVT
vTv Therapeutics Inc. (Class A)
E 24/100 — — -35.0% -4.05% $99.5M /vtvt-vs-orgo →
NTHI
NeOnc Technologies Holdings Inc.
E 31/100 — — -35.0% -5.83% $97.0M /nthi-vs-orgo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001661181 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Organogenesis Holdings Inc. (Class A) (ORGO) reported GAAP revenue of $564.2M (+17.0% vs. FY2024 revenue of $482.0M , and +30.3% cumulative change since FY2023) , GAAP net income of $37.0M, operating cash flow of -$10.3M, and free cash flow of -$24.5M (-685.7% YoY). On the balance sheet, ORGO closed FY2025 with $598.7M in total assets against $0 in total debt (Altman Z-Score: 2.09, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $564.2M $37.0M -$10.3M -$24.5M $598.7M —
FY2024 (FY) 2024-12-31 $482.0M $900.0K $14.2M $4.2M $497.9M —
FY2023 (FY) 2023-12-31 $433.1M $4.9M $30.9M $30.9M — —

3. ORGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ORGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Organogenesis Holdings Inc. (Class A) (NASDAQ: ORGO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $0.76 (-1.64% 1D, market cap $98.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 9/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 8/20. Active quantitative signal LIQUIDITY_TAILWIND (BEARISH, conviction undefined/100) notes: undefined.

How does ORGO compare to PMVP and NRXP in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ORGO carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 17.1%. By comparison, PMVP (PMV Pharmaceuticals Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $98.9M) and NRXP (NRX Pharmaceuticals Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $98.3M). Among the 5-stock peer group, ORGO leads on earnings multiple (N/A) while ORGO leads on capital efficiency (17.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ORGO?

Per ORGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001661181), Organogenesis Holdings Inc. (Class A) generated $564.2M in revenue (+17.0% YoY), $37.0M in net income, and -$24.5M in free cash flow against $598.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ORGO trading relative to its 50-day, 200-day, and 52-week technical levels?

ORGO last traded at $0.76 (-1.64% on volume of 2,279,010 shares), positioning the stock -41.98% below its 50-day simple moving average ($1.31) and -67.52% below its 200-day simple moving average ($2.34). Across its 52-week range of $0.73 to $7.08, ORGO sits at the 0.5% percentile with a 14-day RSI of 20.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.86).

Direct Sub-Reports: ORGO RQD Cockpit ORGO 12M Forecast ORGO Earnings & Move ORGO Dividends & DRIP ORGO Insiders & 13F ORGO Whale Options ORGO Profit Sankey ORGO News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

ORGO — Organogenesis Holdings Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Organogenesis Holdings Inc. (Class A) (ORGO) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.76 (-1.64% 1D, market capitalization $98.8M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of 17.1%, gross margin of —, operating margin of 7.9%, and free cash flow yield of -23.21%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.09, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Organogenesis Holdings Inc. (Class A) (ORGO) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the same section, the company carries a market capitalization of $0.1B. Per the recent news wire, company activity includes a publication of a diabetic foot ulcer trial and an announced Q3 2026 earnings report date.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Organogenesis Holdings Inc. (Class A) (ORGO) reported $564.2M in annual revenue (up from $482.0M in FY2024, +17.0% YoY) and $37.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($433.1M revenue, $4.9M net income) through FY2025, ORGO scaled operating cash flow to -$10.3M and free cash flow to -$24.5M, backed by $598.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -23.21% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.73 – $7.08 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against 7.9% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ORGO carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can ORGO sustain or expand its 7.9% operating margin and 17.1% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $564.2M and free cash flow of -$24.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ORGO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ORGO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Organogenesis Holdings Inc. (Class A) (ORGO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ORGO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ORGO Bull vs. Bear Conversation Board — What's Your Call at $0.76?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ORGO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ORGO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $0.98 (+27.3%)
📌 Pinned Debate

A 17.1% ROIC and a 13/20 whale 13F flow pillar suggest returns and institutional interest that could support the stock if cash conversi

A 17.1% ROIC and a 13/20 whale 13F flow pillar suggest returns and institutional interest that could support the stock if cash conversion improves.. When you look under the hood at ORGO, Fundamental Cash Engine is 8/20 with 0.0% gross margins and 17.1% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $7.08. My 12M target is $0.98.

ArenaChamp_24 🐂 BULL

@AlphaFlow_Cap Agree on the RQD 34/100 quality, though with 1.0 beta I'm scaling in with half-size at $0.77 and keeping dry powder in case we test $0.72.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $0.64 (-16.9%)
Spot @ $0.77

A -23.21% FCF yield and an FY 2025 FCF of -$24.5M mean the current price is not backed by cash generation, weighing on a D-grade RQD.

A -23.21% FCF yield and an FY 2025 FCF of -$24.5M mean the current price is not backed by cash generation, weighing on a D-grade RQD.. Look at the math on ORGO: paying current EV/EBITDA multiples for 17.1% ROIC and 7.9% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $0.68 before getting long.

LIVE TAPE